Yissum, the technology transfer company of the Hebrew University of Jerusalem in Israel, has licensed a novel package of stem cell-related technologies to pharmaceutical and biotechnology company TheraCell.

TheraCell will now further develop and commercialise the technology to build advanced regenerative medicine procedures using stem cells, including spinal fusion.

The licensed technology includes a biologically compatible, oxygenated gel that improves bone regeneration and fusion of bone grafts. This technology will be used in conjunction with TheraCell’s proprietary scaffold technology, to enhance the efficiency of spinal fusion procedures.

Other licensing agreements include deals for novel and efficient methods for purifying and manipulating stem cells derived from patients.

Yissum CEO Yehuda Yarmut said that the ability to ensure adequate oxygen levels for cells can help not only with bone healing and bone stem cells, but also holds great promise for other stem cells, as well as for the survival of engineered tissue and organ grafts.

TheraCell president and CEO Rich Grant said that with this technology the company expects to be able to deliver products that are highly attractive to patients, health care providers and insurance payors, because they will significantly improve outcomes of these costly spine fusion procedures and reduce hospitalisation periods, significantly lowering the cost of treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.